SLN: Silence Therapeutics Plc - ADR Company Profile & Statistics

About

Silence Therapeutics plc focuses on the discovery, development and delivery of novel RNA therapeutics in hematology, cardiovascular and other rare and metabolic indications. The Company's product candidate consist SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein and SLN500 for the treatment of complement-mediated diseases which are in clinical stage. Silence Therapeutics plc is based in London, the United Kingdom.

Info & Links

CEO

Craig Tooman

Headquarters

72 HAMMERSMITH ROAD
LONDON, X0 W14 8TH, UNITED KINGDOM

Auditor

PricewaterhouseCoopers LLP

Share holders

Employees

109

Silence Therapeutics Plc - ADR Statistics

Valuation Measures

Market Capitalization²

204.42M

Enterprise Value

124.03M

Enterprise Value/EBITDA(ttm)

-1.68

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

9.49

Price to Book(mrq)

1.57

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

-91.04%

Operating Margin(ttm)

-342.00%

Profit Margin(ttm)

-1405.70%

Return on Equity(ttm)

-62.81%

Return on Invested Capital(ttm)

-128.14%

Return on Assets(ttm)

-33.89%

Income Statement

Revenue(ttm)

20.78M

Revenue Per Share(ttm)

Gross Profit(ttm)

9.29M

EBITDA(ttm)³

-73.63M

Net Income Available to Common(ttm)

-75.11M

Diluted EPS(ttm)

-1.57

Share Statistics

Beta (5Y Monthly)

1.05

52-Week Change

-50.44%

S&P 500 52-Week Change

25.68%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

Dividend Yield

0.00%

Float⁴

29.05M

% Held by Insiders

2.95%

% Held by Institutions

98.73%

Balance Sheet

Total Cash(mrq)

167.76M

Total Cash Per Share(mrq)

Total Debt(mrq)

180.80K

Total Debt/Equity(mrq)

0.15%

Current Ratio(mrq)

9.31%

Quick Ratio(mrq)

9.31%

Book Value Per Share(mrq)

2.60

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.88

Free Cash Flow(ytd)

-41.72M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

SLN

Silence Therapeutics Plc - ADR

Silence Therapeutics Plc - ADR Profile